Literature DB >> 27600099

Decreased risk of developing cancer in subjects carrying SLC52A3 rs13042395 polymorphism: proof from a meta-analysis.

Jun Li1, Shilong Wang2, Man Li1, Hui Xu2, Dandan Li1, Can Yin1, Jin Zhao1, Feng Li1,3.   

Abstract

AIM: This study aimed to conduct a meta-analysis to explore the association between SLC52A3 rs13042395 polymorphism and cancer risk. MATERIALS &
METHODS: A comprehensive literature search was performed to confirm the relationship evaluated using STATA 12.0 software.
RESULTS: Overall, SLC52A3 rs13042395 C>T polymorphism was associated with cancer risk in two genetic models (TT vs CC: odds ratio: 0.86; 95% CI: 0.80-0.93; p < 0.001, TT vs CC + CT: odds ratio: 0.88; 95% CI: 0.82-0.95; p = 0.001). Significant associations were found between SLC52A3 rs13042395 polymorphism and decreased cancer risk among esophageal cancer, Asians, female, normal BMI and old age groups. No significant associations were observed in alcohol and smoking groups.
CONCLUSION: SLC52A3 rs13042395 C>T polymorphism might be a potential biomarker for cancer susceptibility.

Entities:  

Keywords:  SLC52A3; association; cancer; meta-analysis; rs13042395

Mesh:

Substances:

Year:  2016        PMID: 27600099     DOI: 10.2217/bmm-2016-0158

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  2 in total

Review 1.  Cumulative evidence for association between genetic polymorphisms and esophageal cancer susceptibility: A review with evidence from meta-analysis and genome-wide association studies.

Authors:  Jie Tian; Caiyang Liu; Guanchu Liu; Chunjian Zuo; Huanwen Chen
Journal:  Cancer Med       Date:  2019-02-21       Impact factor: 4.452

2.  Functional variation of SLC52A3 rs13042395 predicts survival of Chinese gastric cancer patients.

Authors:  Xiaofei Qu; Lei Cheng; Liqin Zhao; Lixin Qiu; Weijian Guo
Journal:  J Cell Mol Med       Date:  2020-09-05       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.